MedTrace Logo

ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety Disorder

NCT05749055 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 252

Last updated 2025-09-25

No results posted yet for this study

Summary

The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)

Conditions

  • Generalized Anxiety Disorder

Interventions

DRUG

ENX-102

Selective GABA-A alpha2,3,5 positive allosteric modulator

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • Engrail Therapeutics INC

    lead INDUSTRY

Principal Investigators

  • Estibaliz Arce, PhD · Engrail Therapeutics INC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-03
Primary Completion
2025-09-18
Completion
2025-09-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05749055 on ClinicalTrials.gov